Assembly Biosciences Inc (ASMB)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$20.86+1.41%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put ASMB beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Stabilize or grow revenue after 2026: Comparison needs review.
View ThesisManagement screens strong on capital allocation, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 49% in its worst 12-month stretch.
View RiskASMB’s case rests on strong recent performance and revenue growth, with revenue stabilization after 2026 still under review. Revenue grew 39% year over year in Q2 FY2026, though no earnings release is recorded. ASMB trades at 21× P/E versus a 21× peer median; expectations look modest versus our view. The company remains unprofitable, and the next-quarter miss probability is 30%. Revenue stabilization is the pressured pillar, but the comparison needs review, so no confirmed breach is established. Peer multiples imply a price about 43% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. ASMB is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 5 analysts currently covering ASMB (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for ASMB in the last 4 months.
Continue this research
Compare ASMB with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ASMB Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ASMB next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance ABI-5366 and ABI-1179 clinical programs with Gilead collaboration
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $20.86
The last 12 months of price, then the range of analyst 12-month targets from today’s $20.86.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Gilead advancements positively impact ABI-5366 and ABI-1179 programs.
Advances: Maintain cash position to fund operations into 2028
Earnings beat supports cash position and operational funding.
Advances: Advance ABI-5366 and ABI-1179 clinical programs with Gilead collaboration
Recent updates likely include progress on clinical programs.
Advances: Maintain cash position to fund operations into late 2027
Funding extends cash runway into late 2027.
Advances: Maintain cash position to fund operations into late 2027
Funding extends cash runway into late 2027.
Expansion plan indicates growth potential.